Cell Genesys, Inc.
Records under this name other than patents Cell Genesys, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,919,079 | Cancer Immunotherapy Compositions and Methods of Use Formerly held In force · High confidence | In force | High confidence | |
| US 7,870,581 | Signal processing apparatus and methods Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,901,902 | Methods and Compositions for Identifying a Cellular Immune Response Against Prostate Cancer Formerly held In force · High confidence | In force | High confidence | |
| US 9,669,081 | Methods and Compositions for Treating Prostate Cancer or Inducing a Humoral Immune Response Against Prostate Cancer Formerly held In force · High confidence | In force | High confidence | |
| US 11,497,781 | Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 12,090,183 | Methods of treating solid or lymphatic tumors by combination therapy Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,840,881 | Methods and Compositions for Treating Prostate Cancer or Inducing a Humoral Immune Response Against Prostate Cancer Formerly held Lapsed on the fee record Ended Sep 23, 2026 · High confidence | Lapsed on the fee record | Ended Sep 23, 2026 | High confidence |
| US 7,473,418 | Pan cancer oncolytic vectors and methods of use thereof Formerly held Term ended Term ended Mar 9, 2025 · From the USPTO record | Term ended | Term ended Mar 9, 2025 | From the USPTO record |
| US 7,858,083 | Pan Cancer Oncolytic Vectors and Methods of Use Thereof Formerly held Term ended Ended no later than Mar 9, 2025 · Low confidence | Term ended | Ended no later than Mar 9, 2025 | Low confidence |
| US 7,176,022 | Directly injectable formulations which provide enhanced cryoprotection of cell products Formerly held Term ended Term ended Feb 27, 2024 · From the USPTO record | Term ended | Term ended Feb 27, 2024 | From the USPTO record |